. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Parkinsonism Relat Disord. 2015 Jan 5;21(3):271–276. doi: 10.1016/j.parkreldis.2014.12.027

Table 2.

Demographics and CSF biomarker values of the discovery and validation cohorts at the start of Phase 2 in the DATATOP sample

		Discovery (n=154)	Validation (n=151)	Total (n=305)
Sex, F/M (% male)		48/106 (45.3%)	54/97(55.7%)	102/203 (50.2%)

Age (yrs)	Mean ± SD	62.80 ± 9.57	62.86 ± 9.05	62.83 ± 9.3
Age (yrs)	Range	36 – 79	35 – 80	35 – 80

Disease Duration (yrs)	Mean ± SD	3.82 ± 1.58	3.83 ± 1.42	3.82± 1.5
Disease Duration (yrs)	Range	1 – 8	1 – 9	1 – 9

MMSE	Mean ± SD	28.72 ± 2.30	28.85 ± 2.10	28.79 ± 2.20
MMSE	Range	8 – 30	9 – 30	8 – 30

UPDRS total	Mean ± SD	45.12 ± 13.37	43.84 ± 14.72	44.49 ± 14.05
UPDRS total	Range	10 – 83	8.5 – 88	8.5 – 88

UPDRS motor	Mean ± SD	30.22 ± 10.30	29.61 ± 10.91	29.92 ± 10.59
UPDRS motor	Range	6 – 59	4.5 – 62	4.5– 62

Hoehn and Yahr	Median	2	2	2
Hoehn and Yahr	Range	1 – 3	1 – 4	1 – 4

CSF Aβ₄₂ (pg/mL)	Mean ± SD	233.37 ± 80.06	231.01 ± 72.14	232.21 ± 76.14
CSF Aβ₄₂ (pg/mL)	Range	12.13 – 631.25	15.53 – 464.04	12.13 – 631.25

CSF t-tau (pg/mL)	Mean ± SD	47.67 ± 25.18	46.65 ± 24.94	47.16 ± 25.02
CSF t-tau (pg/mL)	Range	13.38 – 171.80	12.29 – 191.42	12.29 – 191.42

CSF p-tau (pg/mL)	Mean ± SD	22.95 ± 11.11	24.22 ± 13.06	23.58 ± 12.11
CSF p-tau (pg/mL)	Range	3.85 – 62.90	4.35 – 96.93	3.85 – 96.93

CSF p-tau/t-tau	Mean ± SD	0.52 ± 0.21	0.56 ± 0.24	0.54 ± 0.23
CSF p-tau/t-tau	Range	0.16 – 1.09	0.16 – 1.83	0.16 – 1.83

CSF t-tau/Aβ₄₂	Mean ± SD	0.24 ± 0.33	0.22 ± 0.13	0.23 ± 0.26
CSF t-tau/Aβ₄₂	Range	0.10 – 4.14	0.10 – 0.81	0.10 – 4.14

CSF p-tau/Aβ₄₂	Mean ± SD	0.12 ± 0.20	0.12 ± 0.13	0.12 ± 0.17
CSF p-tau/Aβ₄₂	Range	0.03 – 2.45	0.03 – 1.45	0.03 – 2.45

MMSE:Pre-washout Mini Mental State Examination prior to the beginning of Phase 2; UPDRS: Unified Parkinson Disease Rating Scale; CSF: cerebrospinal fluid; Aβ₄₂: amyloid beta peptide 1-42; p-tau: phosphorylated tau; t-tau: total tau.